The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Phase I Clinical Trial for Hepatitis C Drug Starts: ACH-3422

Back to News Homepage

Next

Which Big Name Protease Inhibitor Left the Hepatitis C Market?

Racing to Shorten Duration of Hep C Treatment

June 24, 2014

Print this page

Will cutting HCV treatment time down from 12 weeks to 4 weeks help reduce cost of this cure?
Racing to Shorten Duration of Hep C Treatment

A 4-week hep C cure? Bristol to test drugs with Gilead’s Sovaldi

By Bill Berkrot
NEW YORK Fri Jun 20, 2014

(Reuters) – In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc’s blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.

Bristol-Myers disclosed plans for the exploratory 30-patient trial testing its three-drug combination with Sovaldi in an interview with Reuters. Eric Hughes, the leader of Bristol’s global hepatitis program, said the details were due to be posted on the clinicaltrials.gov website next week.

Continue reading this entire article:
http://www.reuters.com/article/2014/06/20/us-health-hepatitis-bristol-idUSKBN0EV0BL20140620

6 Comments
Share
Share

Previous

Phase I Clinical Trial for Hepatitis C Drug Starts: ACH-3422

Back to News Homepage

Next

Which Big Name Protease Inhibitor Left the Hepatitis C Market?

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.